NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 95.3% and is now trading at $30.96.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) posted its earnings results on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.15. The medical research company had revenue of $46.20 million for the quarter, compared to analyst estimates of $39.63 million. InVitae had a negative net margin of 182.73% and a negative return on equity of 82.78%. The firm's quarterly revenue was down 14.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.54) earnings per share.
View InVitae's earnings history.

6 brokers have issued twelve-month price targets for InVitae's shares. Their forecasts range from $20.00 to $37.25. On average, they expect InVitae's share price to reach $32.54 in the next year. This suggests a possible upside of 5.1% from the stock's current price.
View analysts' price targets for InVitae.

News coverage about NVTA stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. InVitae earned a news impact score of -2.8 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about InVitae.

Some companies that are related to InVitae include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Biocept (BIOC), Enzo Biochem (ENZ) and Anpac Bio-Medical Science (ANPC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Roku (ROKU), Alibaba Group (BABA), Square (SQ), Trade Desk (TTD), Shopify (SHOP), Walt Disney (DIS), salesforce.com (CRM), Twilio (TWLO) and Micron Technology (MU).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Jennison Associates LLC (0.31%), Swiss National Bank (0.21%), Mutual of America Capital Management LLC (0.14%), Profit Investment Management LLC (0.13%) and Moody Aldrich Partners LLC (0.12%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Principal Financial Group Inc., Profit Investment Management LLC, CAPROCK Group Inc., OTA Financial Group L.P., Dupont Capital Management Corp, and Focused Wealth Management Inc. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Fagan Associates Inc., Mackay Shields LLC, Mutual of America Capital Management LLC, Swiss National Bank, AE Wealth Management LLC, Sawtooth Solutions LLC, First Trust Advisors LP, and K.J. Harrison & Partners Inc.
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $30.96.

InVitae has a market capitalization of $3.87 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]